Mandate

Vinge advises Wilson Therapeutics in connection with directed share issue

December 12, 2017

Vinge has advised Wilson Therapeutics on a directed new issue of shares, whereby Wilson Therapeutics raises proceeds of approximately SEK 244 million, before issue costs.

The share issue is directed to a number of selected institutions and sector specialist funds, internationally and in Sweden, on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Christian Lindhé, Erik Sjöman, Mattias Sköld, Ludvig Frithiof and Astrid Karlsson.

Related

Vinge has advised Fortinova Fastigheter in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Fortinova Fastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 12 November 2025 and the trading on Nasdaq Stockholm commenced on 19 November 2025, five years to the day since the first listing.
November 19, 2025

Vinge has advised Lagercrantz Group on the acquisition of Sit Right and Enskede Hydraul

Lagercrantz Group AB (publ) has acquired 70 percent of the shares in the two Swedish companies Sit Right AB and Enskede Hydraul AB, which are leading operators in products and aftermarket parts for forestry and construction machinery in Europe.
November 07, 2025

Vinge advises the founders of NOOS Digital in connection with the merger with Rocket Revenue and 56K Digital

Following the recent merger between Rocket Revenue and 56K Digital, the group now takes its next step by joining forces with NOOS Digital. The three companies will integrate into one of the Nordic region’s most comprehensive partners for digital transformation and business acceleration.
November 04, 2025